Location of Repository

S-nitrosothiols as selective antithrombotic agents - possible mechanisms

By Michael P. Gordge and Fang Xiao


S-nitrosothiols have a number of potential clinical applications, among which their use as antithrombotic agents has been emphasized. This is largely because of their well-documented platelet inhibitory effects, which show a degree of platelet selectivity, although the mechanism of this remains undefined. Recent progress in understanding how nitric oxide (NO)-related signalling is delivered into cells from stable S-nitrosothiol compounds has revealed a variety of pathways, in particular denitrosation by enzymes located at the cell surface, and transport of intact S-nitrosocysteine via the amino acid transporter system-L (L-AT). Differences in the role of these pathways in platelets and vascular cells may in part explain the reported platelet-selective action. In addition, emerging evidence that S-nitrosothiols regulate key targets on the exofacial surfaces of cells involved in the thrombotic process (for example, protein disulphide isomerase, integrins and tissue factor) suggests novel antithrombotic actions, which may not even require transmembrane delivery of NO

Topics: UOW2
Publisher: John Wiley
OAI identifier: oai:westminsterresearch.wmin.ac.uk:7784
Provided by: WestminsterResearch

Suggested articles



  1. 1992a, "Nitric oxide circulates in mammalian plasma primarily as an Snitroso adduct of serum albumin",
  2. 1992b, "S-nitrosylation of tissue-type plasminogen activator confers vasodilatory and antiplatelet properties on the enzyme",
  3. 1993a, "Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor",
  4. (2008). A cystine-cysteine shuttle mediated by xCT facilitates cellular responses to S-nitrosoalbumin",
  5. (2001). A metabolic enzyme for S-nitrosothiol conserved from bacteria to humans",
  6. (2000). A redox site involved in integrin activation",
  7. (2009). Activation and inhibition of soluble guanylyl cyclase by S-nitrosocysteine: involvement of amino acid transport system L", Free radical
  8. (2006). Bacitracin reveals a role for multiple thiol isomerases in platelet function",
  9. (1993). Biological activity of S-nitrosothiols: the role of nitric oxide",
  10. (1998). Cell-free and erythrocytic S-nitrosohemoglobin inhibits human platelet aggregation",
  11. (1999). Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide",
  12. (2005). Characterization of the Sdenitrosation activity of protein disulfide isomerase",
  13. (2007). cyclic GMP-independent inhibition of integrin alphaIIbbeta3-mediated platelet adhesion and outside-in signalling by nitric oxide",
  14. (2006). Cyclic GMP-independent mechanisms contribute to the inhibition of platelet adhesion by nitric oxide donor: a role for alphaactinin nitration",
  15. (2009). Endothelial dysfunction and vascular disease", Acta physiologica
  16. (2004). Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock",
  17. (2008). Globular adiponectin increases cyclic GMP formation in blood platelets independently of nitric oxide",
  18. (2000). Inhibition of human platelet aggregation by a novel S-nitrosothiol is Miller,
  19. (2000). Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cyclic GMP-independent mechanisms",
  20. (1999). Inhibition of platelet aggregation by S-nitroso-cysteine via cyclic GMP-independent mechanisms: evidence of inhibition of thromboxane A2 synthesis in human blood platelets",
  21. (2004). Inhibition of thrombosis by a novel platelet selective S-nitrosothiol compound without hemodynamic side effects",
  22. (2007). Interactions between cell surface protein disulphide isomerase and Snitrosoglutathione during nitric oxide delivery",
  23. (1998). Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase",
  24. (2001). Mechanism of transfer of NO from extracellular S-nitrosothiols into the cytosol by cell-surface protein disulfide isomerase",
  25. (2001). Metabolism of S-nitrosoglutathione by endothelial cells",
  26. (2006). Metalloprotein-dependent decomposition of S-nitrosothiols: Studies on the stabilization and measurement of S-nitrosothiols in tissues", Free Radic Biol Med,
  27. (1999). Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets",
  28. (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor",
  29. (1999). Peroxynitrite-mediated oxidation of fibrinogen inhibits clot formation",
  30. (2004). Platelet cell surface protein disulfide isomerase mediated S-nitrosoglutathione consumption",
  31. (2002). Potential therapeutic uses for Snitrosothiols",
  32. (2004). Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species",
  33. (2008). Protein disulphide isomerase in platelet function",
  34. (2002). Proteins of the PDI family: unpredicted non-ER locations and functions",
  35. (2003). Rapid Snitrosothiol metabolism by platelets and megakaryocytes",
  36. (2007). Recent developments in nitric oxide donor drugs",
  37. (1991). S-nitrosocysteine inhibition of human platelet secretion is correlated with increases in platelet cyclic GMP levels",
  38. (1998). S-nitrosoglutathione inhibits platelet activation and deposition in coronary artery saphenous vein grafts in vitro and in vivo",
  39. (1992). S-nitrosoglutathione inhibits platelet activation in vitro and in vivo",
  40. (1996). S-nitrosoglutathione is cleaved by the thioredoxin system with liberation of glutathione and redox regulating nitric oxide",
  41. (1998). S-nitrosoglutathione reduces the rate of embolization in humans",
  42. (2004). S-nitrosothiols in the blood: roles, amounts, and methods of analysis",
  43. (2005). S-Nitrosothiols: cellular formation and transport",
  44. (2007). S-Nitrosylation of platelet alphaIIbbeta3 as revealed by Raman spectroscopy",
  45. (2005). Specific transport of Snitrosocysteine in human red blood cells: Implications for formation of Snitrosothiols and transport of NO bioactivity within the vasculature",
  46. (2001). Taming platelets with cyclic nucleotides",
  47. (2009). The Janus face of alcohol dehydrogenase 3", Chemico-biological interactions,
  48. (2004). The mechanism of transmembrane S-nitrosothiol transport",
  49. (1987). The role of nitric oxide and cyclic GMP in platelet adhesion to vascular endothelium",
  50. (2007). Tissue factor activation: is disulfide bond switching a regulatory mechanism?",
  51. (2007). Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidoreductase activity",
  52. (2006). Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications",
  53. (2008). Triggers, targets and treatments for thrombosis",
  54. (1990). Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide",

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.